Phase 3 Lymphoma Trial, Recruiting NCT04670029 Sponsor: Weprom Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT04670029
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a specific type of blood cancer called diffuse large B-cell lymphoma, or a slow-growing B-cell lymphoma that has recently changed into a faster-growing type
  • You have either not yet started treatment, or have received no more than 2 cycles of chemotherapy (confirm with trial site)
  • You are 65 years of age or older
  • Your doctor has confirmed you are suitable for a chemotherapy treatment called R-CHOP
  • You are generally able to carry out daily activities with minimal limitations (your doctor will assess this)
  • You are enrolled in a social security or health insurance scheme
  • You are willing and able to give written consent to take part in the study

Who may not be able to join:

  • You have a different type of lymphoma, such as T-cell lymphoma, Burkitt's lymphoma, or a slow-growing B-cell lymphoma that has not transformed
  • The lymphoma has spread to your brain or the fluid around your brain or spine
  • You have a physical disability (movement or sensation) that would prevent you from taking part in adapted physical activity sessions
  • You have high blood pressure that is not currently under control
  • You have serious heart or breathing problems that would prevent you from taking part in physical activity sessions
  • You have a significant condition affecting your bones, joints, or muscles
  • Your heart pumping function is below a certain level, as measured by a heart scan (confirm with trial site)
  • You have already received 3 or more cycles of first-line chemotherapy
  • You are pregnant or breastfeeding
  • You have an active infection of hepatitis B, hepatitis C, or HIV
  • You are under legal guardianship or have had your freedom restricted
  • You have dementia, a significant mental health condition, or a psychiatric illness that could affect your ability to consent or follow the study
  • You are unable to follow the study requirements for personal, social, family, or location-related reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Katell LE DÛ, MD, Clinique Victor Hugo/Centre Jean Bernard

Phone: 0241682940

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Weprom
Registry
ClinicalTrials.gov
Start date
8 September 2021
Est. completion
1 August 2025

Where this trial is recruiting

🇫🇷 France

Primary endpoints

To detect an absolute difference of 15% in event-free survival between the 2 groups

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov